JNJ
Johnson & Johnson
Price performance
Sep 18, 2026About
Company activity
30 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 08/04 | JNJ | 8-K | Johnson & Johnson Announces Retirement of Executive Vice President Jennifer Taubert and Appointment of Tom Cavanaugh | — | — | — |
| 07/29 | JNJ | 8-K | Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. and Updates Financial Guidance | — | — | — |
| 07/27 | JNJ | 8-K | Johnson & Johnson Announces Proposed Resolution of Ovarian Talc Litigation | — | — | — |
| 07/15 | JNJ | 8-K | Johnson & Johnson Reports Strong Q2 2026 Results and Raises Outlook | — | — | — |
| 04/27 | JNJ | 8-K | Johnson & Johnson Shareholders Approve Key Proposals at 2026 Annual Meeting | — | — | — |
| 04/14 | JNJ | 8-K | Johnson & Johnson Reports Strong Q1 2026 Results and Increases Dividend | — | — | — |
| 01/21 | JNJ | 8-K | Johnson & Johnson Announces Strong Q4 and Full-Year 2025 Results | — | — | — |
| 10/14/25 | JNJ | 8-K | Johnson & Johnson Reports Strong Q3 2025 Results and Announces Orthopaedics Business Separation | — | — | — |
| 09/08/25 | JNJ | 8-K | Johnson & Johnson Appoints John Morikis to Board of Directors | — | — | — |
| 07/16/25 | JNJ | 8-K | Johnson & Johnson Reports Q2 2025 Results and Raises Outlook | — | — | — |
| 06/10/25 | JNJ | 8-K | Johnson & Johnson Appoints Daniel Pinto to Board of Directors | — | — | — |
| 04/30/25 | JNJ | 8-K | Johnson & Johnson Director Retirement and Annual Meeting Results | — | — | — |
| 04/15/25 | JNJ | 8-K | Johnson & Johnson Reports Q1 2025 Financial Results with Strong Sales Growth and Dividend Increase | — | — | — |
| 04/03/25 | JNJ | 8-K | Johnson & Johnson Bankruptcy Plan Denied | — | — | — |
| 02/26/25 | JNJ | 8-K | Johnson & Johnson Completes Public Offering of New Notes | — | — | — |
| 02/20/25 | JNJ | 8-K | Johnson & Johnson Completed Public Offerings of Various Notes | — | — | — |
| 01/22/25 | JNJ | 8-K | Johnson & Johnson Reports Q4 2024 Financial Results and Pipeline Progress | — | — | — |
| 01/22/25 | JNJ | 8-K | Johnson & Johnson Reports Q4 and Full-Year 2024 Financial Results and Provides 2025 Guidance | — | — | — |
| 10/15/24 | JNJ | 8-K | Johnson & Johnson Announces Q3 2024 Financial Results and Updates Guidance | — | — | — |
| 09/20/24 | JNJ | 8-K | Johnson & Johnson's Subsidiary Files for Chapter 11 Bankruptcy to Resolve Talc Litigation | — | — | — |
| 09/10/24 | JNJ | 8-K | Johnson & Johnson Announces Retirement of Director D. S. Davis | — | — | — |
| 08/26/24 | JNJ | 8-K | Johnson & Johnson Announces Retirement of Chief Human Resources Officer | — | — | — |
| 07/17/24 | JNJ | 8-K | Johnson & Johnson Reports Q2 2024 Financial Results and Updates Guidance | — | — | — |
| 05/20/24 | JNJ | 8-K | Johnson & Johnson Completes Public Offerings of Multiple Notes | — | — | — |
| 05/17/24 | JNJ | 8-K | Johnson & Johnson Completes Separation from Kenvue via Debt-for-Equity Exchange | — | — | — |
| 05/01/24 | JNJ | 8-K | Johnson & Johnson Announces Plan of Reorganization for Ovarian Cancer Claims | — | — | — |
| 04/29/24 | JNJ | 8-K | Johnson & Johnson Adopts New By-Laws and Shareholder Approvals at 2024 Annual Meeting | — | — | — |
| 04/16/24 | JNJ | 8-K | Johnson & Johnson Corrects Q1 2024 Sales Guidance Midpoint | — | — | — |
| 04/16/24 | JNJ | 8-K | Johnson & Johnson Announces Strong Q1 2024 Performance and Dividend Increase | — | — | — |
| 01/23/24 | JNJ | 8-K | Johnson & Johnson Reports Strong 2023 Financial Results and Key Regulatory Approvals | — | — | — |
JNJ filing record
Johnson & Johnson (JNJ): 30 8-K filings summarized, the most recent on Aug 4, 2026.
What the 8-K filings said
- Aug 4, 2026 · high impact
Johnson & Johnson announced on August 4, 2026, that Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, will retire effective September 1, 2026. Taubert, who has been with the company for over 21 years, will be succeeded by Tom Cavanaugh, currently the Company Group Chairman…
Johnson & Johnson Announces Retirement of Executive Vice President Jennifer Taubert and Appointment of Tom Cavanaugh - Jul 29, 2026 · high impact
Johnson & Johnson (JNJ) has completed the acquisition of Firefly Bio, Inc., a biotechnology company specializing in degrader antibody conjugate (DAC) technology for oncology, for $1 billion in cash. This acquisition, along with a strategic agreement with Sail Biomedicines, is expected to reduce JNJ's adjusted…
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. and Updates Financial Guidance - Jul 27, 2026 · high impact
Johnson & Johnson announced a proposed resolution of the ovarian talc litigation, conditioned on the participation of at least 95% of the remaining claims. The agreement includes a $5.5 billion commitment by the company, with the first payment of no more than $3 billion to be made in 2027. This resolution follows a…
Johnson & Johnson Announces Proposed Resolution of Ovarian Talc Litigation - Jul 15, 2026 · high impact
Johnson & Johnson reported a 6.6% increase in Q2 2026 sales to $25.3 billion, with adjusted operational growth of 5.7%. The company also raised its 2026 outlook, with estimated reported sales now at $101.1 billion and adjusted EPS guidance increased by $0.13 to $11.68. Notable product launches and regulatory approvals…
Johnson & Johnson Reports Strong Q2 2026 Results and Raises Outlook - Apr 27, 2026 · medium impact
At the 2026 Annual Meeting of Shareholders, Johnson & Johnson's shareholders elected all 12 director nominees to the Board of Directors, approved the executive compensation philosophy and compensation of named executive officers on an advisory basis, ratified the appointment of PricewaterhouseCoopers LLP as the…
Johnson & Johnson Shareholders Approve Key Proposals at 2026 Annual Meeting
SEC filings in the last five years
- 55 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 3 Form 8-K/A